Why BGPT?
logo

Review Papers Claim by Claim

Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.

Press Enter ↵ to start review



    Explore by Goal












     Quick Explanation


    BGPT takeaway
    This paper proposes a Ras → JMJD3/KDM6B → H3K27me3 (syntenin promoter) → syntenin → TβRI/Smad2/3 → EMT axis in Ras-activated lung cancer, with JMJD3 inhibition (GSK-J4) reducing migration and tumor growth in vivo. Evidence spans cell-line perturbations, ChIP-qPCR at the syntenin promoter, reporter assays, and xenografts.



     Long Explanation


    Paper Review (evidence-grounded): JMJD3/KDM6B controls TGF-β–induced EMT via epigenetic derepression of syntenin
    Paper: 10.1038/s41389-021-00307-0 • Published: 2021-02 (received/revised/accepted shown in manuscript metadata)
    Mechanism map (from the paper’s proposed causal chain)
    Evidence basis for the chain and the inhibitor effect:
    Evidence coverage across experimental layers
    Layer What was tested Support for causal chain?
    Clinical correlatesGEO expression differences; KM Plotter survival association; correlations with K-Ras/H-RasModerate (association, not causation)
    Ras→JMJD3 regulationCA-KRas/HRas increases JMJD3; DN-HRas suppresses JMJD3; ERK/PI3K inhibitors reduce JMJD3Strong (perturbation evidence in cells)
    JMJD3→TGF-β signaling & EMTJMJD3 knockdown reduces p-Smad2/3 and Smad3 binding/output; JMJD3 overexpression increases phosphorylationStrong (directional signaling evidence)
    Epigenetic mechanism at synteninChIP shows JMJD3 recruitment to syntenin TSS region and changes in H3K27me3 occupancy with Ras and JMJD3 perturbationsStrong-to-moderate (locus-specific ChIP supports mechanism, but still relies on limited loci/assays)
    Syntenin→TβRI/Smad complexJMJD3 or syntenin depletion reduces TβRI; co-IP supports increased TβRI/Smad2/3 complex with JMJD3 overexpression; Ras inhibitor (Salirasib) suppresses recruitmentModerate-to-strong (complex formation supports link)
    PhenotypeTranswell migration (± TGF-β1); EMT markers (vimentin, Slug, E-cadherin); xenograft growth; p-Smad2 IHCModerate-to-strong (functional & in vivo endpoints)
    All rows summarize what the manuscript reports:
    Intervention logic: where GSK-J4 is claimed to act
    Note: this plot encodes only the reported direction (GSK-J4 abolishes migration/EMT and reduces xenograft growth and nuclear p-Smad2), not numeric magnitudes (the full text provided here does not include the raw numbers/plots).
    What the paper claims (mechanistic interpretation)
    • Ras activation upregulates JMJD3/KDM6B in lung cancer contexts, with evidence using constitutively active Ras, dominant-negative Ras, and ERK/PI3K pathway inhibition.
    • JMJD3 is required for TGF-β1-induced Smad2/3 activation and Smad3 transcriptional output, shown via phosphorylation assays, Smad3-target promoter binding/output reporter activity, and reductions in target gene expression upon JMJD3 knockdown.
    • JMJD3 epigenetically derepresses syntenin by reducing H3K27me3 at the syntenin promoter/TSS region, supported by locus-specific ChIP/ChIP-qPCR showing JMJD3 binding and changes in H3K27me3 occupancy upon Ras activation or JMJD3 perturbation.
    • Syntenin mediates the link to TβRI/Smad2/3 complex formation, with JMJD3 or syntenin depletion reducing TβRI levels and JMJD3 or syntenin overexpression increasing TGF-β1-induced TβRI/Smad2/3 complex formation, while Ras inhibition (Salirasib) suppresses Smad2/3 recruitment.
    Skeptical critique (epistemic humility + testability)
    • Specificity of GSK-J4: the paper treats GSK-J4 as a specific JMJD3/KDM6B activity inhibitor; however, inhibitor off-targets are a common concern for epigenetic enzymes (not evaluated here with orthogonal catalytic mutants or multiple chemotypes in the provided text). This means “phenotype ↔ JMJD3 catalytic activity” is plausible but not fully uniquely established from the excerpted evidence alone.
    • Epigenetic scope: ChIP is described at the syntenin TSS region (locus-specific). Whether JMJD3 broadly reshapes H3K27me3 across a broader EMT gene network in these Ras-activated contexts is not established in the excerpt. Thus, syntenin may be central, or one of several relevant targets.
    • Clinical inference limitations: the paper uses GEO microarray and KM Plotter survival association. Such analyses are sensitive to cohort composition, batch effects, and probe-level issues, and correlation with Ras-family expression does not prove the directionality of causation.
    • Model system generality: cell lines and nude-mouse xenografts can miss immune, stromal, and microenvironment influences that modulate TGF-β/EMT programs. The mechanism plausibly transfers, but it is not fully validated across orthogonal in vivo models in the provided text.
    • Mechanistic completeness: the study identifies JMJD3 recruitment and H3K27me3 changes at syntenin and links syntenin to TβRI/Smad2/3 complex formation and EMT markers. Still, the paper’s claim that syntenin is the sole mediator of JMJD3’s pro-EMT effects is not proven in the provided text; other JMJD3 targets could contribute.
    Background sanity-check: JMJD3/UTX as H3K27 demethylases
    The paper builds on canonical chemistry: JMJD3 (and UTX) are reported as H3K27 demethylases that regulate gene expression programs.
    Skeptical note: “enzyme can demethylate” ≠ “this demethylation at this locus is the observed driver of this phenotype in your specific cancer context.” The paper addresses the latter with syntenin-locus ChIP evidence, but without broader epigenomic mapping in the provided text.
    Next actions (BGPT)


    Feedback:    

    Updated: May 02, 2026

     BGPT Paper Review


    Study Novelty

    80%

    Novelty is high because it combines Ras–TGF-β EMT crosstalk with a specific epigenetic mechanism: JMJD3 recruitment and H3K27me3 demethylation at the syntenin promoter leading to TβRI/Smad2/3 activation and EMT, plus a GSK-J4 in vivo validation in the provided text.


    Scientific Quality

    80%

    Scientific quality is strong: multiple perturbation modalities (siRNA/shRNA/overexpression), pathway inhibition, mechanistic ChIP/ChIP-qPCR at a defined regulatory locus, reporter assays, complex formation readouts, functional migration/invasion, and an in vivo xenograft endpoint with molecular marker (p-Smad2). Major remaining red flags are specificity/orthogonality of inhibitor action (in the provided text) and locus specificity vs genome-wide epigenetic scope.


    Study Generality

    70%

    Generality is moderate: the mechanism is demonstrated in Ras-activated lung cancer cell contexts and xenograft models, but translation to other Ras-driven cancers and to different EMT/EMT-plasticity states is not established in the provided text.


    Study Usefulness

    80%

    High usefulness for mechanistic cancer epigenetics: it provides a concrete, testable axis (JMJD3 → syntenin promoter H3K27me3 → TβRI/Smad2/3 → EMT) with multiple measurable intermediate states (ChIP occupancy, Smad phosphorylation, EMT markers).


    Study Reproducibility

    60%

    Reproducibility is moderate: methods are described (ChIP, reporter assays, transwell, xenografts, statistics), but the provided text does not include detailed primer sequences/tables for all loci nor raw data availability statements beyond supplementary info. Inhibitor off-target and batch effects in clinical datasets add variability.


    Explanatory Depth

    80%

    Explanatory depth is high because it proposes a mechanistic chain with direct intermediate-state evidence: promoter-level epigenetic occupancy (JMJD3 binding/H3K27me3 at syntenin TSS), gene expression (syntenin), receptor signaling support (TβRI/Smad complex), and downstream EMT outputs.


    🎁 Authors: Collect 344 Free Science Tokens (≈ $34.4 USD)

    Claim My Author Tokens

    Use for 86 days of free BGPT access (4 tokens = 1 day) or trade/sell (≈ $34.4 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    I will ingest the paper’s described GEO cohort and compute expression/survival associations for JMJD3 and Ras markers, then visualize correlation patterns and survival stratifications to quantify reported strengths.



     Hypothesis Graveyard


    JMJD3 promotes EMT primarily by global H3K27me3 loss across the whole EMT network (rather than locus-specific syntenin promoter control); this is less favored because the provided evidence emphasizes syntenin promoter ChIP/ChIP-qPCR and syntenin-linked downstream readouts rather than genome-wide profiling.


    GSK-J4 reduces migration and tumor growth mainly through off-target effects unrelated to JMJD3 catalytic activity; this remains possible in principle, but the paper’s intermediate-state alignment (JMJD3-related ChIP and syntenin/TβRI/Smad readouts) argues that JMJD3-dependent mechanisms are at least plausibly engaged.

     Science Art


    Paper Review: Epigenetic regulation of TGF-β-induced EMT by JMJD3/KDM6B histone H3K27 demethylase Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending